Budget impact analysis on erythropoiesis–stimulating agents use for the management of chemotherapy-induced anaemia in Greece

Cost Effectiveness and Resource Allocation

Mary Geitona¹  Magdalini Hatzikou¹  Eleftheria Nikolaidi¹ 

[1] School of Social Sciences, University of Peloponnese, Corinth, Greece

关键词: Greece;    Erythropoiesis Stimulating agents (ESAs);    Biosimilars;    Budget impact;   

Others  :  810615
DOI  :  10.1186/1478-7547-11-16

 received in 2012-12-07, accepted in 2013-07-12,  发布年份 2013

【 摘 要 】

Background

Chemotherapy-induced anaemia is a common and significant complication of chemotherapy treatment. Blood transfusion and administration of Erythropoiesis-Stimulating Agents (ESAs) either alone or in combination with iron are the most widely used therapeutic options. In Greece, ESAs are among the top ten therapeutic groups with the highest pharmaceutical expenditure, since they are fully reimbursed by social security funds. The objective of the study is to determine potential cost savings related with the use of biosimilar over originator ESAs for the management of the newly diagnosed chemotherapy-induced anemic patients.

Methods

A budget impact analysis has been carried through the elaboration of national epidemiological, clinical and economic data. Epidemiological data derived from WHO (GLOBOCAN) and the European Cancer Anaemia Survey. Clinical data reflect oncology patients’ disease management. ESAs consumption was based on data from the biggest social security fund (IKA). The administration of ESAs under different dosing schemes and time periods has been estimated by separating them in originators and biosimilars as well as by classifying anaemic patients in responders and non-responders. Cost analysis is based on newly diagnosed patients’ alternative treatment scenarios. Treatment costs and prices are used in 2012 values. The Social Security Funds’s perspective was undertaken.

Results

Based on the annual incidence rates, 2.551 newly diagnosed chemotherapy-induced anemic patients are expected to be treated with ESAs. Average cost of treatment on originators ESAs for responders is €2.887 for the 15-week ESAs treatment and €5.019 for non-responders, while on biosimilars €2.623 and €4.009 respectively. Treatment cost on biosimilars is 10.1% lower than originators for responders and 25.2% for non-responders. Budget impact estimates show that treating anemic patients with originator ESAs was estimated at €10.084.800 compared to €8.460.119 when biosimilar ESAs were used, leading to an overall 19,20% cost reduction favoring biosimilars.

Conclusion

In Greece, the treatment on biosimilar ESAs seems to be a cost saving option over originators for the newly diagnosed chemotherapy-induced anemic patients, since it corresponds to 5% of the annual overall consumption and expands patients’ access to ESAs treatment. Health care decision making should rely on evidence based treatments in order to achieve social funds’ sustainability in an era of economic recession.

【 授权许可】

   
2013 Nikolaidi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gasco P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D: The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004, 40:2293-2306.
• [2]Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
• [3]Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB: Cancer-and Chemotherapy-Induced Anaemia. J Natl Compr Canc Netw 2012, 10:628-653.
• [4]Aapro M, Link H: Update on EORTC guidelines and anaemia management with erythropoiesis-stimulating agents. Oncologist 2008, 13(Suppl. 3):33-36.
• [5]Aapro M, Cornes P, Sun D, Abraham I: Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis – stimulating agent to manage chemotherapy – induced anaemia in patients with cancer. Therapeutic Advances Med Oncol 2012, 0(0):1-11.
• [6]Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007, 43:258-270.
• [7]Society of Thoracic Surgeons Blood Conservation Guideline Task Force: Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline. Ann Thorac Surg 2007, 83:S27-S86.
• [8]Repetto L, Moeremans K, Annemans L: European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment. Cancer Treat Rev 2006, 32(Suppl 2):S5-S9.
• [9]Aapro MS, Birgegård G, Bokemeyer C, Cornes P, Foubert J, Gascon P, Glaspy J, Hellström-Lindberg E, Link H, Ludwig H, Osterborg A, Repetto L, Soubeyran P: Erythropoietins should be used according to guidelines. Lancet Oncol 2008, 9(5):412-413.
• [10]Upile T, Jeries W, Sandison A, Singh S, Rhys-Evans P, Sudhoff H, Hopper C: The direct effects of stored blood products may worsen prognosis of cancer patients; shall we transfuse or not? An explanation of the adverse oncological consequences of blood product transfusion with a testable hypothesis driven experimental research protocol. Med Hypotheses 2008, 71:498-492.
• [11]Auerbach M, Ballard H, Trout JR, McIIwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anaemia: a multicenter, open label, randomized trial. J Clin Oncol 2004, 22:1301-1307.
• [12]Auerbach M, Silberstein PT, Webb RT, Averyanove A, Ciuleanu TE, Shao J, Bridges K: Darbepoetin alfa 300 or 500μg once every 3 weeks with or without intravenous iron in patients with chemotherapy induced anaemia. Am J Hematol 2010, 85:655-663.
• [13]Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF: Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every three weeks with or without intravenous iron in patients with chemotherapy-induced anaemia. J Clin Oncol 2008, 26:1611-1618.
• [14]Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y: Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 2012, 23:1954-1962.
• [15]Szucs TD, Blank PR, Schwenkglenks M, Aapro M: Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer or chemotherapy – induced anaemia. Oncology 2011, 81:45-49.
• [16]Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma D, Djulbegovic B, Fey M, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373:1532-1542.
• [17]Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Julbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert : A Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev 2010, 11:CD007303.
• [18]Cella D: The effects of anaemia and anaemia treatment on the quality of life of people with cancer. Oncology (Williston Park) 2002, 16(suppl 10):125-132.
• [19]Cella D, Kallich J, McDermott A, Xu X: The longitudinal relationship of hemoglobin, fatigue and quality of life in anaemic cancer patients: Results from five randomized clinical trials. Ann Oncol 2004, 15:979-986.
• [20]Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, Wiebe N, Klarenbach S: Benefits and harms of erythropoiesis-stimulating agents for anaemia related to cancer: a meta-analysis. CMAJ 2009, 180(11):E62-E71.
• [21]Kanavos P, Yfantopoulos J, Vandoros C, Politis C: The economics of blood: gift of life or a commodity? Int J Technol Assess Health Care 2006, 22(3):338-43.
• [22]Pronzato P, Cortesi E, Ritjt C, Bois A, Moreno-Nogueira J, Freire de Oliveira C, Barrett-Lee P, Ostler PJ, Rosso R: Epoetin Alfa Improves Anaemia and Anaemia-Related, Patient-Reported Outcomes in Patients with Breast Cancer Receiving Myelotoxic Chemotherapy: Results of a European, Multicenter, Randomized, Controlled Trial. Oncologist 2010, 15:935-943.
• [23]Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo controlled trial. J Clin Oncol 2001, 19:2865-2874.
• [24]Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levit R, Morton RF: Phase III, randomized, double- blind study of epoetin alfa compared with placebo in anaemic patients receiving chemotherapy. J Clin Oncol 2005, 23:2606-2617.
• [25]Tonia T, Mettler A, Robert N, et al.: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012, 12:CD003407.
• [26]Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE: Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents. PharmacoEconomics 2008, 26(2):99-120.
• [27]Schellekens H: Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004, 3:43-7.
• [28]Rovira J, Espin J, Garcia L, De Labry A: The impact of biosimilars’ entry in the EU market. Andalusian Sch Pub Health 2011, 30:1-83.
• [29]Chow SC, Endrenyi L, Lachenbruch PA, Yang LY, Chi E: Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics. Biosimilars 2011, 1:13-26. http://www.dovepress.com webcite
• [30]Karalis V, Symillides M, Macheras P: Novel methods to assess bioequivalence. Expert Opin Drug Metab Toxicol 2011, 7(1):79-88.
• [31]Bhupinder SS, Vikrant S: Biosimilars: an overview. Biosimilars 2011, 1:1-11. http://www.dovepress.com webcite
• [32]EMEA: uideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision) EMEA/CHMP/BMWP/301636/2008 Corr.*. London, United Kingdom: The European Medicines Agency Evaluation of Medicines for Human Use; 2010.
• [33]Schrijvers D, De Samblanx H, Roila F, ESMO Guidelines Working Group: Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010, 21(Supplement 5):244-247.
• [34]Kani C, Litsa P, Alexopoulou Hatzikou M, Delibasi S, Geitona M: Striving for Affordable treatments within the Greek environment: Do epoetin biosimilars help? Value Health 2011, 14:412-413.
• [35]Geitona M: Assessing the value of medicinal innovation in an era of increasing austerity. Soc Cohesion Dev 2012, 7(1):39-51.
• [36]International Agency for Research on Cancer – World Health Organization, (IARC-WHO), Globocan. 2008. http://globocan.iarc.fr webcite
• [37]US National Comprehensive Cancer Network, NCCN: Clinical Practice Guidelines in Oncology, Cancer- and Chemotherapy- Induced Anaemia. http://www.nccn.org/index.asp webcite
• [38]National Organization for Medicines, EOF. http://www.eof.gr webcite
• [39]European Society for Medical Oncology (ESMO). http://www.esmo.org webcite